Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.1.4.3 (phospholipase C)
18,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Kinins elicit prostaglandin and inositol phosphate production in 3T3 fibroblasts through stimulation of B2 receptors. Prostaglandin synthesis is maximum by 5 min, whereas inositol phosphate production continues for longer than 30 min. Prostaglandin synthesis is stimulated by phospholipase A2, which releases arachidonate from phospholipids, whereas a phosphatidylinositol-specific phospholipase C catalyzes formation of equimolar amounts of inositol phosphate and diacylglycerol. Stimulation of these two second-messenger systems occurs through independent pathways: (a) dexamethasone inhibits prostaglandin formation by inhibiting phospholipase A2, and, to a lesser degree, cyclooxygenase, but is without effect on inositol phosphate production; (b) neomycin inhibits inositol phosphate production without affecting prostaglandin synthesis; (c) phorbol esters inhibit inositol phosphate production while augmenting prostaglandin synthesis; and (d) indomethacin inhibits prostaglandin synthesis but does not affect inositol phosphate production. At later times (greater than 10 min), the two pathways interact. Stimulation with one agonist to increase diacylglycerol results in augmentation of prostaglandin synthesis in response to a second agonist. Inositol phosphates cause release of calcium from intracellular stores. Prostaglandins stimulate (by binding to their own receptors) adenylate cyclase to increase cAMP. Additionally, prostaglandins increase intracellular free calcium by increasing influx of extracellular calcium. Both inositol phosphates and prostaglandins play roles in mitogenesis in these cells.
...
PMID:Kinin signal transduction: role of phosphoinositides and eicosanoids. 169 60

1. rPDGF stimulates PGE2 release in wild type, but not ras transformed NIH-3T3 cells. 2. Ras transformation blocks PGE2 release by inhibiting phospholipase C activation, IP3 synthesis, and Ca2+ mobilization. 3. rPDGF stimulation of wild type NIH-3T3 cells increases both prostaglandin H synthase (PGHS) mRNA levels and PGHS enzyme levels as measured by immunoblot. However, PGHS gene transcription is not required for PDGF-stimulated PGE2 release. 4. Ras transformed NIH-3T3 cells display elevated basal PGE2 synthesis, and very high levels of both PGHS mRNA and enzyme. rPDGF does not further stimulate PGHS gene transcription. 5. Exogenous PGE2 attenuates rPDGF-stimulated cell proliferation in both wild type and ras transformed cells. 6. These data suggest that increased PGHS gene expression and enhanced basal PGE2 synthesis may be in response to the unregulated growth of ras transformed cells.
Adv Prostaglandin Thromboxane Leukot Res 1991
PMID:Elevated prostaglandin H synthase gene expression in ras-transformed cells. 182 90

The activity of partially purified phospholipase C from human platelets was totally dependent on Ca2+, and approximately 800 microM Ca2+ was required for half-maximal activity. The enzyme hydrolyzed endogenous substrates in the order DPI greater than TPI greater than PI in a Ca2+-dependent manner. Hydrolysis of TPI in thrombin-stimulated platelets was dependent on the amount of the agonist, and it was not affected by the presence or absence of extracellular Ca2+. Hydrolysis was inhibited by preincubation with Quin-2AM in the absence of extracellular Ca2+. The intracellular Ca2+ concentration was significantly lowered below the basal level by such treatment. These observations suggested that TPI breakdown in thrombin-stimulated platelets is mediated by agonist-receptor coupling and requires at least the basal level of intracellular Ca2+.
Adv Prostaglandin Thromboxane Leukot Res 1985
PMID:Ca2+ requirement in hydrolysis of phosphatidylinositol-4,5-bisphosphate in human platelets. 300 31

We studied the effects of platelet-activating factor (PAF-acether) on phospholipase activity in renal epithelial cells. When platelet-activating factor was added to renal cells prelabeled with [3H]arachidonic acid, it induced the rapid hydrolysis of phospholipids. Up to 26% of incorporated [3H]arachidonic acid was released into the medium from renal cells. After the addition of PAF-acether, the degradation of phosphatidylcholine, phosphatidylinositol and phosphatidylethanolamine were observed. The amount of [3H]arachidonic acid released were comparable to the losses of phosphatidylcholine, phosphatidylinositol and phosphatidylethanolamine. In renal cells biosynthetically labeled by incorporation of [3H]choline into cellular phosphatidylcholine, lysophosphatidylcholine and sphingomyelin, the range of concentrations of PAF-acether-induced hydrolysis of labeled phosphatidylcholine were approximately equal to the amounts of lysophosphatidylcholine produced. We also observed a transient rise of diacylglycerol after the addition of platelet-activating factor to these cells. To test for action of phospholipase C, the accumulations of [3H]choline, [3H]inositol and [3H]ethanolamine were determined. The radioactivities in choline and ethanolamine showed little or no change. An increase in inositol was detectable within 1 min and it peaked at 3 min. These results indicate that platelet-activating factor stimulates phospholipase A2 and phosphatidylinositol-specific phospholipase C activity in renal epithelial cells. These phospholipase activities were Ca2+ dependent. Moreover, PAF-acether enhanced changes in cell-associated Ca2+. These results suggest that the increased Ca2+ permeability of cell membrane stimulates phospholipases A2 and C in renal epithelial cells. Prostaglandin biosynthesis was also enhanced in these cells by platelet-activating factor.
...
PMID:Effect of platelet-activating factor on arachidonic acid metabolism in renal epithelial cells. 308 Oct 36

We have studied the effects of elastase on phospholipase activity in aortic smooth muscle cells and have found that when added to cells prelabeled with [3H]arachidonic acid, elastase induced rapid phospholipid hydrolysis, resulting in release of up to 18% of incorporated [3H]arachidonic acid into the medium. Maximum stimulation by elastase without any cellular damage was observed at a concentration of 50 units/ml. At higher concentrations (75-100 units/ml), release of arachidonic acid was still observed, but cells were damaged. After the addition of elastase, degradation of phosphatidylcholine, phosphatidylinositol and phosphatidylethanolamine was observed and it was found that their loss was comparable to the amount of [3H]arachidonic acid released. In aortic smooth muscle cells biosynthetically labeled by the incorporation of [3H]choline, [3H]inositol and [3H]ethanolamine into cellular phosphatidylcholine, phosphatidylinositol and phosphatidylethanolamine, respectively, the amount of phosphatidylcholine and phosphatidylethanolamine hydrolyzed following elastase-treatment was not equal to the amounts of lysophosphatidylcholine and lysophosphatidylethanolamine produced. We also observed a transient rise in diacylglycerol after the addition of elastase. To test for phospholipase C activity, the release of incorporated [3H]choline, [3H]inositol and [3H]ethanolamine into the culture medium was determined. The levels of radioactive choline and ethanolamine showed increases, but the change in inositol was comparatively small. An increase in inositol was detectable within 1 min after elastase addition, and peaked after 15 min, whereas increases in choline and ethanolamine continued for up to 60 min. These results indicate that elastase stimulated the activities of phospholipases A2 and C. Both were shown to be Ca2+-dependent, and it was found that, moreover, elastase enhanced Ca2+ influx. These results suggest increased cell-membrane permeability to Ca2+-stimulated phospholipases A2 and C. Prostaglandin biosynthesis in these cells was also enhanced by elastase.
...
PMID:Effect of elastase on phospholipase activity in aortic smooth muscle cells. 312 84

Prostaglandin (PG) F2 alpha increased [3H]thymidine incorporation into quiescent NIH 3T3 cells, stimulated phosphoinositide breakdown, and raised intracellular Ca2+ concentration ([Ca2+]i) in a dose-dependent manner with ED50 values of 2.0 x 10(-8) M, 4.6 x 10(-8) M, and 7.5 x 10(-8) M, respectively. The increase in [3H]thymidine incorporation with PGF2 alpha was additive with that seen with epidermal growth factor (EGF) or insulin. The peak [Ca2+]i increase with PGF2 alpha was still obvious in the absence of extracellular Ca2+ and was insensitive to islet activating protein (IAP) pretreatment. Membranes prepared from NIH 3T3 cells exhibited a specific binding for PGF2 alpha, which was sensitive to GTP gamma S but not sensitive to IAP pretreatment. Xenopus laevis oocytes injected with NIH 3T3 cell mRNA between 18S and 28S rRNA fractionated by sucrose gradient, expressed a PGF2 alpha-specific Cl- current when examined by voltage clamp. This Cl- current was also insensitive to IAP pretreatment and not affected by extracellular Ca2+ concentration ([Ca2+]o). These results indicate 1) that the NIH 3T3 cells expressed a specific PGF2 alpha receptor which is linked to phosphoinositide-specific phospholipase C (PLC) activation and to mobilization of Ca2+ via an IAP-insensitive G-protein(s), 2) that this PGF2 alpha receptor may play an active role in the proliferation of NIH 3T3 cells, and 3) that this PGF2 alpha receptor can be expressed in the oocyte system.
...
PMID:Characterization of prostaglandin F2 alpha receptor of mouse 3T3 fibroblasts and its functional expression in Xenopus laevis oocytes. 848 18

Prostaglandin (PG) F(2alpha), a member of the prostanoid bioactive lipid family, is secreted by human endometrium throughout the menstrual cycle and is present in both menstrual fluid and medium of endometrial explants in culture. PGF(2alpha) mediates its effects through a seven-transmembrane G-protein-coupled receptor (FP). The aim of this study was to examine the temporal expression, signaling, and role of FP receptor in the human endometrium. Quantitative RT-PCR analysis demonstrated highest expression of FP receptor in the mid- to late-proliferative phase, compared with early-proliferative and secretory phase endometrium. In situ hybridization studies localized FP receptor mRNA expression to the epithelial cell compartment during the mid- to late-proliferative phase. Moreover, treatment of endometrial tissue with 1-100 nM PGF(2alpha) induced a concentration-dependent increase in inositol phosphate mobilization, indicating functional FP receptor expression. The Ishikawa human endometrial epithelial cell line was used to investigate further the signaling and role of PGF(2alpha) in endometrial epithelial cells. Ishikawa cells endogenously express the FP receptor, and treatment with 1-100 nM PGF(2alpha) elicits a concentration-dependent increase in inositol phosphate release. Moreover, treatment of Ishikawa cells with 100 nM PGF(2alpha) induced phosphorylation of ERK1/2 that was abolished when cells were cotreated with 50 micro M PD98059 (MAPK kinase inhibitor) or 10 micro M U73122 [phospholipase C (PLC) inhibitor]. Treatment of Ishikawa cells with PGF(2alpha) for 24 h induced a significant concentration-dependent increase in Ishikawa cell proliferation. Coincubation of the cells with 50 micro M PD98059 or 2 micro M U73122 demonstrated that PLC inhibition significantly reduced PGF(2alpha)-induced proliferation, whereas MAPK kinase inhibition had no effect. In summary, these studies demonstrate increased FP receptor expression in endometrial epithelial cells during the proliferative phase of the menstrual cycle and identify a role for PGF(2alpha) in epithelial cell proliferation via a PLC-dependent pathway.
...
PMID:Prostaglandin (PG) F(2alpha) receptor expression and signaling in human endometrium: role of PGF(2alpha) in epithelial cell proliferation. 1267 80

Prostaglandin F(2 alpha)(PGF(2 alpha)) is a bioactive lipid biosynthesized by cyclooxygenase (COX) enzymes and mediates its biological activity via the heptahelical G(q)-coupled PGF(2 alpha)receptor (FP receptor). This study investigated the expression and molecular signaling of the FP receptor in human endometrial adenocarcinomas. Real-time RT-PCR and Western blot analysis confirmed FP receptor expression in endometrial adenocarcinoma of all grades and differentiation. The expression of FP receptor was up-regulated in all endometrial adenocarcinomas compared with normal endometrium. The site of FP receptor expression was localized by in situ hybridization and immunohistochemistry to the neoplastic epithelial cells in all adenocarcinomas. Treatment of endometrial adenocarcinoma explants with PGF(2 alpha) resulted in mobilization of inositol phosphate signaling, indicating functional FP receptor expression. We investigated whether PGF(2 alpha) could trans-activate the epidermal growth factor receptor (EGFR) and trigger the MAPK signaling pathway. Treatment of adenocarcinoma explants and endometrial adenocarcinoma cells (Ishikawa) with PGF(2 alpha)-phosphorylated EGFR, triggered MAPK signaling and enhanced the proliferation of Ishikawa cells. Inactivation of phospholipase C, EGFR kinase, and MAPK kinase with specific inhibitors abolished PGF(2 alpha)-induced trans-activation of EGFR, MAPK signaling, and Ishikawa cell proliferation. These data suggest that PGF(2 alpha)-FP receptor promote endometrial tumorigenesis via a phospholipase C-mediated phosphorylation of the EGFR and MAPK signaling pathways.
...
PMID:Expression, localization, and signaling of prostaglandin F2 alpha receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways. 1476 25

Phospholipase A2 (PLA2) is pivotal in the rapid membrane-mediated actions of 1,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3]. Microarray analysis indicated that PLA2 activating protein (PLAA) mRNA is upregulated 6-fold before rat growth plate cells exhibit 1alpha,25(OH)2D3-dependent protein kinase C (PKC) increases, suggesting that it plays an important role in 1alpha,25(OH)2D3's mechanism of action. PLAA mRNA was confirmed in 1alpha,25(OH)2D3-responsive growth zone (prehypertrophic and upper hypertrophic cell zones) chondrocytes by RT-PCR and Northern blot in vitro and by in situ hybridization in vivo. PLAA protein was shown by Western blot and immunohistochemistry. PLAAs role in 1alpha,25(OH)2D3 signaling was evaluated in growth zone cell cultures using PLAA peptide. Arachidonic acid release was increased as was PLA2-specific activity in plasma membranes and matrix vesicles. PKCalpha, but not PKCbeta, PKCepsilon, or PKCzeta, was increased. PLAAs effect was comparable to that of 1alpha,25(OH)2D3 and was additive with 1alpha,25(OH)2D3. PLA2 inhibitors quinacrine and AACOCF3, and cyclooxygenase inhibitor indomethacin blocked the effect of PLAA peptide on PKC, indicating arachidonic acid and its metabolites were involved. This was confirmed using exogenous arachidonic acid. Prostaglandin acted via EP1 based on inhibition by SC19220 and not via EP2 since AH6809 had no effect. Like 1alpha,25(OH)2D3, PLAA peptide also increased activity of phospholipase C-specific activity via beta-1 and beta-3 isoforms, but not delta-1 or gamma-1; the effect of PLAA was via lysophospholipid but not via arachidonic acid. PLAA peptide decreased [3H]-thymidine incorporation to 50% of the decrease caused by 1alpha,25(OH)2D3. In contrast, PLAA peptide increased alkaline phosphatase-specific activity and proteoglycan production in a manner similar to 1alpha,25(OH)2D3. This indicates that PLAA is a specific activator of PLA2 in growth plate chondrocytes, and suggests that it mediates the membrane effect of 1alpha,25(OH)2D3, thereby modulating physiological response.
...
PMID:Phospholipase A2 activating protein (PLAA) is required for 1alpha,25(OH)2D3 signaling in growth plate chondrocytes. 1536 40

The binding of hormones and growth factors to their cell surface receptors leads to an orderly cascade of events leading to activation of cytoplasmic effector molecules. The mechanism of action of luteinizing hormone involves the stimulation of multiple signal transduction effector systems including adenylyl cyclase and inositol phospholipid-specific phospholipase C (PLC). This results in the formation of second messengers that activate cAMP-dependent, Ca(2+)-dependent and lipid-dependent protein kinases. Prostaglandin F(2alpha) activates PLC which increases intracellular calcium and activates protein kinase C. This results in the activation of a series of protein kinases in the mitogen-activated protein (MAP) kinase cascade, leading to the activation of nuclear transcription factors c-fos and c-jun. Hormone responsive effector systems, therefore, operate by activating families of protein kinases which regulate cell metabolism, secretion, and gene transcription. Growth factors activate specific receptor protein tyrosine kinases which recruit additional signaling molecules (phospholipase Cgamma, phosphatidylinositol 3-kinase, Shc, Grb2, etc.) initiating a cascade of events mediated via MAP kinases. The signaling pathways activated by hormones interact or cross talk with the signaling pathways activated by growth factors. The diversity of cellular signaling mechanisms elicited by hormones and the potential for interactions with signals generated by growth factor receptor tyrosine kinases, may allow fine tuning of cellular responses during the life span of the corpus luteum.
...
PMID:Mechanisms of hormone and growth factor action in the bovine corpus luteum. 1672 86


1 2 Next >>

---